In his role as an Associate Director on the Research Programs team, Andrew helps manage the Target Advancement Program.
Specifically, Andrew manages a portfolio of programs designed to help feed new, innovative targets into the therapeutic development pipeline for PD.
He received his B.S. in Biochemistry from the University of Delaware and then worked as a research technician at the US Army Medical Research Institute of Chemical Defense before beginning his graduate work at The Ohio State University. After receiving his Ph.D. in Biomedical Sciences, Andrew moved on to the Icahn School of Medicine at Mount Sinai, where he published research on the role of epigenetics in axonal regeneration in spinal cord injury. Before joining MJFF, Andrew was at the Alzheimer’s Drug Discovery Foundation, working closely with the Alzheimer’s research community to fund programs in neurodegenerative disease drug discovery and development.
Outside of his work at the Foundation, Andrew enjoys spending time with family and friends, staying active, and is a huge soccer fan.